abstract |
The invention concerns the use of tricyclic isoindole derivatives of general formula (I) to manufacture antiviral drugs. In formula (I), X stands for an oxygen or a sulphur atom, the imino group =NH or an N-C1-C5 alkylimino group, Y stands for an oxygen or a sulphur atom, or an NH-, C1-C5 alkylamino group, C1-C5-alkylocarbonylamino, sulphinyl or sulphonyl group, R stands for a hydrogen atom, an aliphatic residue with 1-9 carbon atoms, optionally substituted with phenyl, a phenyl ring, a carbocyclic ring with 7-15 carbon atoms or a heterocyclic ring system in which each ring has 5 or 6 atoms, R<1> and R<2> stand for a hydrogen atom, an aliphatic residue with 1-6 carbon atoms or C1-C6 alkoxy, C1-C6 alkymercapto, C1-C6 alkylsulphinyl, C1-C6 alkylsulphonyl, amino, C1-C6 alkylamino, di-C1-C6 alkylamino, sulphonamido, C1-C6 alkoxycarbonyl, carboxy, halogen, hydroxy, nitro, cyano, azido, phenyl or benzyloxy, R<3> and R<4> stand for hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkymercapto, amino, C1-C6 alkylamino, di-C1-C6 alkylamino, halogen, cyano, hydroxy, carboxy or C1-C6 alkoxycarbonyl. The invention also concerns the physiologically acceptable salts and the optically active derivatives of the compounds of the formula (I). |